Bemotrizinol became legal to use in US sunscreens on August 9, 2026, after a 21-year regulatory wait. Here is what the filter actually does, how it compares to avobenzone and zinc oxide, and when it will realistically reach shelves.
· 6 min read
Bemotrizinol has been sitting on European and Asian shelves for more than two decades, but as of August 9, 2026, it is legally usable in US sunscreens for the first time [1][4]. The FDA added it to the permitted list of sunscreen active ingredients on June 9, 2026, closing a gap that had left American formulators working with the same short bench of UV filters since the late 1990s [1]. Here is what actually changed, why it took this long, and when the first bottles are realistically going to show up on a US shelf.
The FDA's approval and its effective date are two different milestones, and mixing them up is the easiest way to misread this story. The agency finalized its order allowing bemotrizinol on June 9, 2026, then set August 9, 2026 as the date manufacturers could legally start formulating with it [1][4][5]. That means no US sunscreen sold before this month legally contains it, no matter what a label claims. The ingredient itself was originally submitted for review back in 2005 and only moved after a 2024 refiling used a faster regulatory pathway created for over-the-counter drug reviews [4].
The core reason bemotrizinol needed 21 years to clear is regulatory classification, not safety concern. The US treats sunscreen as an over-the-counter drug, which triggers the FDA's full drug-review process. Europe and much of Asia classify sunscreen as a cosmetic, so the same molecule cleared those markets in a fraction of the time [4]. Bemotrizinol has been sold internationally under the name Tinosorb S since the late 1990s, which is part of why dermatologists interviewed after the US approval described the underlying safety data as already well established rather than new [3][4].
Bemotrizinol is a single molecule with two separate UV-absorption peaks, one around 310nm in the UVB range and another around 340nm in the UVA1 range, so it covers both bands without needing to be paired with a second filter [3]. That is a meaningful shift for US formulas: avobenzone, the workhorse UVA filter in most current American sunscreens, degrades in sunlight and can lose up to 36% of its protective capacity within about an hour of UV exposure unless it is stabilized with other ingredients [3]. Bemotrizinol is reported to retain more than 98% of its UV-absorbing capacity even after 50 minimal erythemal doses of simulated sun exposure, which is the kind of photostability that reduces how often reapplication is needed to maintain the labeled protection level [3].
Zinc oxide remains the filter dermatologists most often point to as a baseline, largely because it sits on top of skin rather than absorbing into it, though it can leave a visible cast that some people find cosmetically unappealing [2]. Bemotrizinol does not leave that white cast, and its relatively large molecular weight, about 627.81 g/mol, limits how much of it passes into skin compared with older chemical filters [2][3]. It also carries no reported estrogenic activity, a distinction some dermatologists have raised specifically because it separates bemotrizinol from a couple of older chemical filters that drew scrutiny on that point [3]. None of this makes it a replacement for mineral formulas across the board; it is better read as a third option that fills the gap between effective-but-chalky mineral formulas and cosmetically elegant filters that tend to break down in sunlight.
Because it is new to US shelves, it is fair to ask what evidence backs it. Reporting on the approval points to more than two decades of real-world use across European and Asian markets without significant safety signals turning up in that time, and to that international track record as the basis for the FDA's determination that it is generally recognized as safe and effective for people ages 6 months and up [2][3]. That is a different evidentiary picture than a brand-new compound with no usage history, and it is worth saying plainly: current chemical UV filters are absorbed into the body to varying degrees, and long-term absorption research is still an active area of study industry-wide, a point one oncology-focused source raised directly when covering this approval [2]. Bemotrizinol's lower absorption profile is a specific, cited advantage on that front, not a guarantee that eliminates the broader question.
Set expectations carefully here, because approved and available are not the same thing. DSM-Firmenich, which markets the ingredient as PARSOL Shield in the US, holds exclusive marketing rights through roughly early 2028, an 18-month window from the effective date [4][5]. Formulation, stability testing, packaging, and distribution all still have to happen after the August 9 effective date, which is why most coverage points to products first reaching shelves in fall 2026 at the earliest, with broader distribution more realistically landing in late 2026 or into 2027 [1][2][5]. Kenvue, the parent company behind several major US sunscreen brands, has already signaled plans to work bemotrizinol into its lineup, which is a reasonable early signal of who moves first, though a specific product list is not yet public [5].
When bottles do show up, the ingredient list may not say bemotrizinol outright. Four names can legitimately appear depending on the brand and where the formula was originally developed: bemotrizinol (the US-approved name), BEMT (the cosmetic-chemistry shorthand), Tinosorb S (the long-standing European trade name), and PARSOL Shield (DSM's US market name) [5]. If a US label uses any of those four, it is describing the same underlying filter molecule that cleared the FDA in June.
Nothing changes about your routine today just because this ingredient exists. Continue using a broad-spectrum sunscreen you actually reapply, since consistent use matters more than which specific filter is in the bottle. When bemotrizinol formulas do reach shelves later this year, they are worth a look if you have found current chemical sunscreens prone to fading by midday, or if you have avoided mineral formulas because of the visible cast, since photostability and a lighter finish are the two changes most directly backed by the cited research above. Check the ingredient list for bemotrizinol, BEMT, Tinosorb S, or PARSOL Shield rather than relying on front-of-bottle marketing, since broader product rollouts typically trail regulatory approval by months. And as always, talk to your doctor about sun protection choices if you have specific skin concerns, since a general guide like this one is not a substitute for individual medical advice.
Rituelle reads your skin over time and adapts your routine to it.
Get the app
Sun & UV
New York's UV Index is still hitting the high range this week even as kids head back to school, and the science behind the old 80-percent-by-18 sun exposure claim points the bigger risk at the parents dropping them off. Here is what the only study to actually measure cumulative UV dose by age found instead.
5 min read
Dryness & Barrier
Urea is usually filed under humectant and forgotten, but published reviews show it also boosts how much of whatever you apply next gets into skin. That is a real interaction, not a mixing myth, and it changes how you should layer it.
5 min read
Pairing & Conflicts
The warning against combining niacinamide and vitamin C traces to a single 1962 hydrolysis experiment on dry powder, not a finished skincare formula. Here is what that study actually measured and why it does not apply to the products on your shelf.
5 min read
